{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "31833846",
  "DateCompleted": {
    "Year": "2021",
    "Month": "02",
    "Day": "05"
  },
  "DateRevised": {
    "Year": "2023",
    "Month": "11",
    "Day": "03"
  },
  "Article": {
    "ArticleDate": [],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "10.1097/GRF.0000000000000513"
    ],
    "Journal": {
      "ISSN": "1532-5520",
      "JournalIssue": {
        "Volume": "63",
        "Issue": "1",
        "PubDate": {
          "Year": "2020",
          "Month": "Mar"
        }
      },
      "Title": "Clinical obstetrics and gynecology",
      "ISOAbbreviation": "Clin Obstet Gynecol"
    },
    "ArticleTitle": "Immunotherapy for Gynecologic Cancer: Current Applications and Future Directions.",
    "Pagination": {
      "StartPage": "48",
      "EndPage": "63",
      "MedlinePgn": "48-63"
    },
    "Abstract": {
      "AbstractText": [
        "The role of the immune system in the development of cancer has been a subject of ongoing clinical investigation in recent years. Emerging data demonstrate that tumorigenesis resulting in ovarian, uterine, and cervical cancers is a consequence of impaired host immune responses to cancerous cells. Leveraging the immune system through the use of immune checkpoint inhibitors, therapeutic vaccine therapy, and adoptive cell transfer presents a profound opportunity to revolutionize cancer treatment. This review will encompass the role of the immune system in development of gynecologic cancers and highlight recent data regarding immunotherapy applications in ovarian, uterine, and cervical cancers."
      ]
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Gynecologic Oncology."
          }
        ],
        "LastName": "Lynam",
        "ForeName": "Sarah",
        "Initials": "S"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Center for Immunotherapy Roswell Park Comprehensive Cancer Center, Buffalo, New York."
          }
        ],
        "LastName": "Lugade",
        "ForeName": "Amit A",
        "Initials": "AA"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Gynecologic Oncology."
          },
          {
            "Identifier": [],
            "Affiliation": "Center for Immunotherapy Roswell Park Comprehensive Cancer Center, Buffalo, New York."
          }
        ],
        "LastName": "Odunsi",
        "ForeName": "Kunle",
        "Initials": "K"
      }
    ],
    "GrantList": [
      {
        "GrantID": "T32 CA108456",
        "Acronym": "CA",
        "Agency": "NCI NIH HHS",
        "Country": "United States"
      }
    ],
    "PublicationTypeList": [
      "Journal Article",
      "Research Support, N.I.H., Extramural",
      "Review"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "United States",
    "MedlineTA": "Clin Obstet Gynecol",
    "NlmUniqueID": "0070014",
    "ISSNLinking": "0009-9201"
  },
  "MeshHeadingList": [
    {
      "QualifierName": [],
      "DescriptorName": "Female"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Forecasting"
    },
    {
      "QualifierName": [
        "therapy"
      ],
      "DescriptorName": "Genital Neoplasms, Female"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [
        "trends"
      ],
      "DescriptorName": "Immunotherapy"
    }
  ],
  "CoiStatement": "<b>Conflict-of-interest disclosure:</b> The authors declare no competing financial interests."
}